Extended Data Fig. 2: Quantification of humoral responses in plasma of vaccinated rhesus macaques.
From: Vaccine plus microbicide effective in preventing vaginal SIV transmission in macaques
a) Plasma antibody titers against ∆V1 gp120 over the course of immunization in the vaccine+SAMT-247 group (n = 20) and vaccine group (n = 18). b) Plasma antibody responses against different peptides encompassing V1 (peptides 15–24) and V2 (peptides 25–29) loop regions of gp120 in the vaccine+SAMT-247 group (n = 20) and vaccine group (n = 18). (c-e) Comparison of c) ADCC titer (P = 0.44), d) V2-specific (NCI05-specific) ADCC activity (P = 0.33) and e) V2-specific (NCI09-specific) ADCC activity (P = 0.13) at week 17 in the vaccine+SAMT-247 group (n = 20) and vaccine group (n = 18). (f-g) Correlation of f) ADCC activity and g) ADCC titer in the vaccine group (n = 18). (h-i) Correlation of h) ADCC activity and i) ADCC titer in the vaccine+SAMT-247 group (n = 20), (j-m) V2-specific (NCI05 and NCI09-specific) ADCC activity with number of intra-vaginal challenges in the vaccine group (n = 18) and vaccine+SAMT-247 group (n = 20). Data shown in (a, c-e) were analyzed with the two-tailed Wilcoxon signed-rank test or two-tailed Mann-Whitney test. Data shown in (f-m) were analyzed with the two-tailed Spearman correlation test. Horizontal and vertical bars denote mean and SD.
